FORT LAUDERDALE, Fla., Aug. 6, 2024 /PRNewswire/ — Anju Software is proud to introduce MA Knowledge, a mobile application enhancing field rep efficiency by providing meticulously curated medical information. As the newest addition to Anju’s Medical Affairs Suite, MA Knowledge empowers Medical Science Liaisons (MSLs) and field reps by efficiently filtering content to deliver relevant, credible, customer-centric content.
MA Knowledge leverages diverse sources like IRMS-CM and preferred content repositories to provide expert answers swiftly in the field. Available as a standalone tool or an addition to Anju’s IRMS MAX solution, it streamlines information retrieval with approved, curated content.
“We’re excited to introduce MA Knowledge into the Medical Affairs space. MA Knowledge enables Medical Affairs teams to curate content from diverse sources of content and make it directly available to field-based medical personnel in one, easy-to-use application,” said Larry Birch, CEO of Anju.
The application enhances content delivery with a seamless, responsive experience across devices, adapting to user behavior to maximize impact during clinician visits. Key features include Smart Filtering to refine scientific content, robust search capabilities, a dynamic workspace for accessing curated content, intuitive Smart Tiles for organizing information, and downloadable content for convenient offline access.
Empower your field reps with MA Knowledge – where precision, efficiency, and credibility converge. Experience the future of medical content delivery with MA Knowledge today. For more information or to schedule a demo of MA Knowledge, contact the Anju team at info@anjusoftware.com.
About Anju
Anju Software is a customer-first organization providing adaptable life science solutions for clinical research, medical affairs, and data science. TrialMaster, IRMS MAX, and TA Scan, the company’s flagship products, lead the way in reducing complexities in the drug and device discovery and commercialization process. Anju is a portfolio company of Abry Partners serving the worldwide pharmaceutical, biotech and contract research Life Sciences markets.
Media Contact
John F. Kouten
JFK Communications, Inc.
+1 609.241.7352
jfkouten@jfkhealth.com
SOURCE Anju Software
SEATTLE, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
– Data support initiation of a combination cohort in the ongoing Phase 1 clinical trial…
SPRING, Texas, Dec. 06, 2025 (GLOBE NEWSWIRE) -- Io Therapeutics, Inc., a privately held pharmaceutical…
Ficerafusp alfa 750mg QW in combination with pembrolizumab demonstrates consistent overall response rate and safety…
TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed…
Demonstrated meaningful overall anemia responses across all patient subgroups, regardless of baseline transfusion status Anemia response…